EVH Quote, Financials, Valuation and Earnings

Cryo-Cell International has a net margin of -13.36% compared to Evolent Health's net margin of 4.49%. Evolent Health's return on equity of -10.73% beat Cryo-Cell International's return on equity of --.

Evolent Health has a consensus price target of $15.08, signalling upside risk potential of 31.79%. On the other hand Cryo-Cell International has an analysts' consensus of $8.50 which suggests that it could grow by 73.12%. Given that Cryo-Cell International has higher upside potential than Evolent Health, analysts believe Cryo-Cell International is more attractive than Evolent Health.

Evolent Health has a beta of 1.015, which suggesting that the stock is 1.544% more volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.659, suggesting its less volatile than the S&P 500 by 34.131%.

Evolent Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 13.24% to investors and pays a quarterly dividend of $0.15 per share. Evolent Health pays -32.59% of its earnings as a dividend. Cryo-Cell International pays out 502.5% of its earnings as a dividend.

Evolent Health quarterly revenues are $483.6M, which are larger than Cryo-Cell International quarterly revenues of $7.9M. Evolent Health's net income of -$64.6M is lower than Cryo-Cell International's net income of $355.8K. Notably, Evolent Health's price-to-earnings ratio is -- while Cryo-Cell International's PE ratio is 498.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolent Health is 0.55x versus 1.27x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

Omnicell has a net margin of -13.36% compared to Evolent Health's net margin of -2.6%. Evolent Health's return on equity of -10.73% beat Omnicell's return on equity of 1.73%.

Evolent Health has a consensus price target of $15.08, signalling upside risk potential of 31.79%. On the other hand Omnicell has an analysts' consensus of $43.33 which suggests that it could grow by 55.99%. Given that Omnicell has higher upside potential than Evolent Health, analysts believe Omnicell is more attractive than Evolent Health.

Evolent Health has a beta of 1.015, which suggesting that the stock is 1.544% more volatile than S&P 500. In comparison Omnicell has a beta of 0.761, suggesting its less volatile than the S&P 500 by 23.879%.

Evolent Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omnicell offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolent Health pays -32.59% of its earnings as a dividend. Omnicell pays out -- of its earnings as a dividend.

Evolent Health quarterly revenues are $483.6M, which are larger than Omnicell quarterly revenues of $269.7M. Evolent Health's net income of -$64.6M is lower than Omnicell's net income of -$7M. Notably, Evolent Health's price-to-earnings ratio is -- while Omnicell's PE ratio is 60.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolent Health is 0.55x versus 1.14x for Omnicell. Usually stocks with elevated PS ratios are considered overvalued.

Phreesia has a net margin of -13.36% compared to Evolent Health's net margin of -3.38%. Evolent Health's return on equity of -10.73% beat Phreesia's return on equity of -16.36%.

Evolent Health has a consensus price target of $15.08, signalling upside risk potential of 31.79%. On the other hand Phreesia has an analysts' consensus of $32.14 which suggests that it could grow by 18.87%. Given that Evolent Health has higher upside potential than Phreesia, analysts believe Evolent Health is more attractive than Phreesia.

Evolent Health has a beta of 1.015, which suggesting that the stock is 1.544% more volatile than S&P 500. In comparison Phreesia has a beta of 0.719, suggesting its less volatile than the S&P 500 by 28.109%.

Evolent Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phreesia offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolent Health pays -32.59% of its earnings as a dividend. Phreesia pays out -- of its earnings as a dividend.

Evolent Health quarterly revenues are $483.6M, which are larger than Phreesia quarterly revenues of $115.9M. Evolent Health's net income of -$64.6M is lower than Phreesia's net income of -$3.9M. Notably, Evolent Health's price-to-earnings ratio is -- while Phreesia's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolent Health is 0.55x versus 3.62x for Phreesia. Usually stocks with elevated PS ratios are considered overvalued.

Premier has a net margin of -13.36% compared to Evolent Health's net margin of 10.36%. Evolent Health's return on equity of -10.73% beat Premier's return on equity of 3.44%.

Evolent Health has a consensus price target of $15.08, signalling upside risk potential of 31.79%. On the other hand Premier has an analysts' consensus of $22.00 which suggests that it could grow by 4.71%. Given that Evolent Health has higher upside potential than Premier, analysts believe Evolent Health is more attractive than Premier.

Evolent Health has a beta of 1.015, which suggesting that the stock is 1.544% more volatile than S&P 500. In comparison Premier has a beta of 0.559, suggesting its less volatile than the S&P 500 by 44.103%.

Evolent Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Premier offers a yield of 4% to investors and pays a quarterly dividend of $0.21 per share. Evolent Health pays -32.59% of its earnings as a dividend. Premier pays out 79.64% of its earnings as a dividend. Premier's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Evolent Health quarterly revenues are $483.6M, which are larger than Premier quarterly revenues of $261.4M. Evolent Health's net income of -$64.6M is lower than Premier's net income of $27.1M. Notably, Evolent Health's price-to-earnings ratio is -- while Premier's PE ratio is 38.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolent Health is 0.55x versus 1.62x for Premier. Usually stocks with elevated PS ratios are considered overvalued.